NANX · Nanophase Technologies Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.06M | $52.35M | $37.30M | $37.32M | $29.48M | $17.12M |
| Cost of Revenue | $46.00M | $36.16M | $29.47M | $28.96M | $20.79M | $11.13M |
| Gross Profit | $16.06M | $16.19M | $7.83M | $8.36M | $8.69M | $5.99M |
| R&D | $4.09M | $3.84M | $3.84M | $3.04M | $2.23M | $1.57M |
| SG&A | $10.40M | $7.22M | $7.53M | $7.58M | $3.90M | $2.93M |
| Total Operating Expenses | $60.27M | $48.11M | - | - | - | - |
| D&A | $897.0K | $928.0K | $742.0K | $567.0K | $454.0K | $358.0K |
| Operating Income | $1.57M | $5.13M | ($3.55M) | ($2.26M) | $2.56M | $1.49M |
| Interest Expense | - | $670.0K | $838.0K | $382.0K | $1.15M | $496.0K |
| Income Tax | $73.0K | $227.0K | $6.0K | ($17.0K) | $37.0K | - |
| Net Income | $1.79M | $4.24M | ($4.39M) | ($2.62M) | $2.32M | $989.0K |
| EPS - Basic | $0.03 | $0.07 | ($0.09) | ($0.05) | $0.05 | $0.03 |
| EPS - Diluted | $0.02 | $0.07 | ($0.09) | ($0.05) | $0.05 | $0.03 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.29M | $1.41M | $1.72M | $2.19M | $657.0K | $957.0K |
| Accounts Receivable | $6.84M | $4.87M | $3.47M | $4.73M | $3.94M | $2.93M |
| Inventory | $18.51M | $20.27M | $10.03M | $8.84M | $6.09M | $4.34M |
| Accounts Payable | $4.10M | $9.09M | $6.26M | $6.36M | $3.57M | $2.13M |
| Current Assets | $28.78M | $29.35M | $16.30M | $16.63M | $11.60M | $8.84M |
| Total Assets | $50.05M | $50.00M | $32.88M | $33.56M | $28.39M | $13.54M |
| Current Liabilities | $13.93M | $25.77M | $15.59M | $16.84M | $8.73M | $6.78M |
| Long-term Debt | - | - | - | $1.00M | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $17.63M | $14.95M | $1.90M | $5.65M | $7.46M | $2.73M |
| Retained Earnings | ($98.64M) | ($100.43M) | ($104.66M) | ($100.07M) | ($97.45M) | ($99.77M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.57M) | $1.97M | ($2.01M) | ($1.65M) | $2.32M | ($2.06M) |
| Investing Cash Flow | ($2.14M) | ($4.56M) | ($1.05M) | ($2.82M) | ($1.87M) | ($878.0K) |
| Financing Cash Flow | $10.59M | $2.27M | $2.59M | $6.00M | ($747.0K) | $2.70M |
| CapEx | - | $4.56M | $1.05M | $2.82M | $1.87M | $878.0K |
| Free Cash Flow | - | ($2.59M) | ($3.06M) | ($4.47M) | $447.0K | ($2.94M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 25.9% | 30.9% | 21.0% | 22.4% | 29.5% | 35.0% |
| Operating margin | 2.5% | 9.8% | -9.5% | -6.1% | 8.7% | 8.7% |
| EBITDA margin | 4.0% | 11.6% | -7.5% | -4.5% | 10.2% | 10.8% |
| Net margin | 2.9% | 8.1% | -11.8% | -7.0% | 7.9% | 5.8% |
| Free cash flow margin | - | -4.9% | -8.2% | -12.0% | 1.5% | -17.2% |
| FCF / Net income | - | -0.61 | 0.70 | 1.71 | 0.19 | -2.97 |
| R&D / Revenue | 6.6% | 7.3% | 10.3% | 8.1% | 7.6% | 9.2% |
| SG&A / Revenue | 16.8% | 13.8% | 20.2% | 20.3% | 13.2% | 17.1% |
| Effective tax rate | 3.9% | 5.1% | - | - | 1.6% | - |
| Return on assets | 3.6% | 8.5% | -13.4% | -7.8% | 8.2% | 7.3% |
| Return on equity | 10.2% | 28.3% | -230.8% | -46.4% | 31.1% | 36.2% |
| Return on invested capital | - | - | - | -26.8% | - | - |
| Liquidity | ||||||
| Current ratio | 2.07 | 1.14 | 1.05 | 0.99 | 1.33 | 1.30 |
| Quick ratio | 0.74 | 0.35 | 0.40 | 0.46 | 0.63 | 0.66 |
| Cash ratio | 0.09 | 0.05 | 0.11 | 0.13 | 0.08 | 0.14 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.18 | - | - |
| Debt / Assets | - | - | - | 0.03 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | 7.7x | -4.2x | -5.9x | 2.2x | 3.0x |
| Equity multiplier | 2.84 | 3.35 | 17.29 | 5.94 | 3.80 | 4.96 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 1.24 | 1.05 | 1.13 | 1.11 | 1.04 | 1.26 |
| Inventory turnover | 2.49 | 1.78 | 2.94 | 3.28 | 3.41 | 2.57 |
| Days sales outstanding | 40d | 34d | 34d | 46d | 49d | 62d |
| Days inventory outstanding | 147d | 205d | 124d | 111d | 107d | 142d |
| Days payable outstanding | 33d | 92d | 78d | 80d | 63d | 70d |
| Cash conversion cycle | 155d | 147d | 81d | 78d | 93d | 135d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 18.6% | 40.4% | -0.1% | 26.6% | 72.1% | 20.6% |
| Revenue CAGR (3y) | 18.5% | 21.1% | 29.6% | 38.0% | - | 11.1% |
| Revenue CAGR (5y) | 29.4% | 29.8% | - | 24.5% | 22.3% | 10.7% |
| Gross profit growth (YoY) | -0.8% | 106.9% | -6.4% | -3.8% | 45.1% | 129.0% |
| Operating income growth (YoY) | -69.4% | - | -57.0% | - | 72.3% | - |
| Net income growth (YoY) | -57.7% | - | -67.4% | - | 134.6% | - |
| EPS growth (YoY) | -71.4% | - | -80.0% | - | 66.7% | - |
| EPS CAGR (3y) | - | 11.9% | - | - | - | - |
| EPS CAGR (5y) | -7.8% | - | - | - | - | - |
| FCF growth (YoY) | - | 15.4% | 31.7% | - | - | 16.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 18.0% | 685.8% | -66.3% | -24.3% | 173.2% | 80.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$124.13M totalProduct$61.79M · 49.8%
Consumer Products$54.87M · 44.2%
Personal Care Ingredients$6.34M · 5.1%
Advanced Materials$857.0K · 0.7%
Product And Service Other$270.0K · 0.2%
Geographic
$5.17M totalNon Us$5.17M · 100.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✓Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Perfumes, Cosmetics & Other Toilet Preparations
Comparing NANOPHASE TECHNOLOGIES Corp against the 5 most active filers in the same SIC group.